Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Ph ‐negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Society for Blood and Marrow Transplantation

American Journal of Hematology, EarlyView.
Source: American Journal of Hematology - Category: Hematology Source Type: research

Related Links:

We report our experience with radiation-free conditioning using busulfan and cyclophosphamide in 127 pediatric patients with acute lymphoblastic leukemia who were treated between 1997 and 2014. The median age was 11 years (range,
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - Category: Transplant Surgery Authors: Tags: Exp Clin Transplant Source Type: research
AbstractPurpose of ReviewCellular therapy using T cells modified to express chimeric antigen receptors (CAR-T cells) has had striking success in patients that have failed previous treatment for CD19+ B cell non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), or acute lymphoblastic leukemia (ALL). Curative therapy for this group of diseases has previously been limited to allogeneic hematopoietic cell transplantation HCT (alloHCT). The recent results of CAR-T cell therapy raise the question of how best to integrate CAR-T cell therapy and alloHCT in the care of these patients.Recent FindingsWithin the past 2  ...
Source: Current Hematologic Malignancy Reports - Category: Hematology Source Type: research
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
Abstract On March 29, 2018, the FDA granted accelerated approval for blinatumomab (Blincyto; Amgen, Inc.) for the treatment of adults and children with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. Blinatumomab is a CD3xCD19 bispecific antibody approved previously for the treatment of relapsed or refractory BCP-ALL. The basis for this accelerated approval was a single-arm trial. For the 86 patients in first and second complete remission with MRD greater than or equal to 0.1%, conversion to MRD
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
We report a relapsed ALL patient who presented with 2 separate chloromas and cerebrospinal fluid lymphoblastocytosis, and outline a treatment plan of systemic chemotherapy and CNS-directed radiation therapy. A review of the literature indicates that multiagent chemotherapy combined with CNS radiotherapy is effective, with hematopoietic stem cell transplantation used in half of reported cases. We conclude that intensive systemic multiagent chemotherapy with CNS-directed radiation therapy can be successfully used to treat relapsed pediatric ALL with CNS lymphoblastic chloroma.
Source: Journal of Pediatric Hematology Oncology - Category: Hematology Tags: Online Articles: Original Articles Source Type: research
Publication date: Available online 20 September 2018Source: Best Practice &Research Clinical HaematologyAuthor(s): Mark R. LitzowAbstractBefore the advent of tyrosine kinase inhibitors (TKIs), Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL) was associated with dismal survival without allogeneic hematopoietic stem cell transplantation (allo-HSCT). Recent evidence has demonstrated that the combination of TKI and chemotherapy can result in a high rate of complete remission, thereby enabling more patients to proceed to allo-HSCT. However, with more studies reporting non-inferior outcomes with TKI and chemother...
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic neoplasm derived from plasmacytoid dendritic cells. Skin lesions are the most common presenting clinical feature, seen in nearly 85% of patients. While some patients may present with disease localized to the skin, most present with or eventually develop systemic involvement most commonly involving the bone marrow.[1 –3] Patients have a median survival of 12 months, and to date therapeutic options remain limited in scope and effectiveness, with the only curative option being stem cell transplant (SCT) therapy in eligible patients.[4] Mos...
Source: Leukemia Research - Category: Hematology Authors: Tags: Research paper Source Type: research
AbstractChimeric antigen receptor (CAR) T-cell therapy has shown promise for relapsed/refractory malignancies. Many patients have undergone prior hematopoietic stem cell transplant (HSCT), yet effects of transplant status on CAR T-cell therapy efficacy and safety have not been reported. The purpose of the study is to systematically evaluate the likelihood of achieving optimum response, severe cytokine release syndrome (sCRS), and neurotoxicity in the context of CAR T-cell therapy for HSCT-na ïve patients versus those with prior HSCT. Trials were identified in, Cochrane Library, and PubMed, and throu...
Source: Medical Oncology - Category: Cancer & Oncology Source Type: research
Refractory acute leukemia has a dismal prognosis and represents a tremendous therapeutic challenge. Conventional allogeneic hematopoietic stem cell transplantation (HSCT) yields long-term survival in only 7% to 24% of patients with refractory acute lymphoblastic leukemia and in only 10% to 40% of those with late-stage acute myelogenous leukemia (AML) [1-6]. Although several recent studies of allogeneic HSCT using 2 grafts (ie, double-umbilical cord blood [UCB] transplantation [dUCBT]) and haploidentical cord blood (haplo-cord) HSCT have shown an enhanced graft-versus-leukemia (GVL) effect along with a graft-versus-graft (G...
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Abstract PURPOSE: The goal of this study was to evaluate the incidence, inpatient mortality, and economic burden of hepatic veno-occlusive disease (VOD) in adults with B-cell acute lymphoblastic leukemia (ALL) in the United States. METHODS: Using MarketScan Commercial Claims and Encounters Database and Medicare Supplemental and Coordination of Benefits Database, data for patients with B-cell ALL from April 1, 2009, to October 31, 2016, were extracted by using diagnosis codes. VOD was identified based on clinical criteria and expert opinions. Patients with VOD were followed up from diagnosis of VOD until the e...
Source: Clinical Therapeutics - Category: Drugs & Pharmacology Authors: Tags: Clin Ther Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Hematology | Leukemia | Stem Cell Therapy | Stem Cells | Transplants